» Articles » PMID: 36845894

Non-pharmacologic Interventions to Improve Depression and Anxiety Among Pregnant and Parenting Women Who Use Substances: An Integrative Literature Review

Overview
Specialty Psychiatry
Date 2023 Feb 27
PMID 36845894
Authors
Affiliations
Soon will be listed here.
Abstract

Pregnant and parenting women who use substances report high rates of comorbid depression and anxiety. Due to the significant impact of this comorbidity on treatment adherence and maternal/child outcomes, effective psychosocial and behavioral interventions to address depression and anxiety in this population are necessary. A directed search of PubMed, PsycINFO, and CINAHL databases produced 22 articles from 20 distinct studies examining non-pharmacologic interventions with an effect on depression and anxiety among pregnant or parenting women using substances. Of the 20 studies reviewed, 8 were randomized controlled trials, 7 were quasi-experimental studies, and 5 were cohort studies. Results revealed a wide array of interventions targeting intrapersonal, interpersonal, and/or structural factors within these women's lives. Parenting therapy and psychosocially enhanced treatment programs had the strongest evidence for positive treatment effect in improving symptoms of depression and anxiety. The use of contingency-management, case-managed care, patient or wellness navigators, mindfulness-based therapy, maternal-child relationship-focused therapy, family therapy, peer support, and therapeutic community-based interventions show promise but warrant further experimental exploration. Comprehensive and gender-specific residential treatment was observationally associated with improvements in depression and anxiety; however, the specific modality of efficacy is unclear. Future research should focus on identifying which modalities are most cost-effective, feasible, and acceptable among this uniquely vulnerable population.

References
1.
Crummy E, ONeal T, Baskin B, Ferguson S . One Is Not Enough: Understanding and Modeling Polysubstance Use. Front Neurosci. 2020; 14:569. PMC: 7309369. DOI: 10.3389/fnins.2020.00569. View

2.
Kim H, Hodgins D . Component Model of Addiction Treatment: A Pragmatic Transdiagnostic Treatment Model of Behavioral and Substance Addictions. Front Psychiatry. 2018; 9:406. PMC: 6127248. DOI: 10.3389/fpsyt.2018.00406. View

3.
McHugh R, Wigderson S, Greenfield S . Epidemiology of substance use in reproductive-age women. Obstet Gynecol Clin North Am. 2014; 41(2):177-89. PMC: 4068964. DOI: 10.1016/j.ogc.2014.02.001. View

4.
Apollonio D, Philipps R, Bero L . Interventions for tobacco use cessation in people in treatment for or recovery from substance use disorders. Cochrane Database Syst Rev. 2016; 11:CD010274. PMC: 6464324. DOI: 10.1002/14651858.CD010274.pub2. View

5.
Conway K, Compton W, Stinson F, Grant B . Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006; 67(2):247-57. DOI: 10.4088/jcp.v67n0211. View